Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 1085-1091

  Montero, Abelardo ^a,c   Ariza, Javier ^a   Corbella, Xavier ^a   Doménech, Alejandro ^a   Cabellos, Carmen ^a   Ayats, Josefina ^b   Tubau, Fe ^b   Borraz, Carmen ^b   Gudiol, Francesc ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c NONE   (Spain)

Author keywords

A. baumannii; Animals; Experimental; Multiresistant

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM; COLISTIMETHATE; IMIPENEM; RIFAMPICIN; SULBACTAM; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; STRAIN DIFFERENCE; TREATMENT OUTCOME; VALIDATION PROCESS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; RIFAMPIN; TOBRAMYCIN;

EID: 12344303247     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh485     Document Type: Article

References (46)

1. Basustaoglu, A. C., Kisa, O., Sacilik, S. C. et al. (2001). Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methods. Journal of Hospital Infection 47, 246-9.
2. Bergogne-Bérézin, E. & Towner, K. J. (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews 9 148-65.
3. Fluit, A. C., Jones, M. E., Schmitz, F. J. et al. (2000). Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clinical Infectious Diseases 30, 454-60.
4. Forster, D. H. & Daschner, F. D. (1998). Acinetobacter species as nosocomial pathogens. European Journal of Clinical Microbiology and Infectious Diseases 17, 73-7.
5. Anon. (1996). National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. American Journal of Infection Control 24, 380-8.
6. Levin, A. S. S., Mendes, C. M. F., Sinto, S. I. et al. (1996). An outbreak of multiresistant Acinetobacter baumannii in a University Hospital in Sao Paulo, Brazil. Infection Control and Hospital Epidemiology 17, 366-8.
7. Manikal, V. M., Landman, D., Saurina, G. et al. (2000). Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clinical Infectious Diseases 31, 101-6.
8. Afzal-Shah, M., Woodford, N. & Livermore, D. M. (2001). Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 45, 583-8.
9. Bou, G., Cerveró, G., Domínguez, M. A. et al. (2000). Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. Journal of Clinical Microbiology 38, 3299-305.
10. Fierobe, L., Lucet, J. C., Decre, D. et al. (2001). An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infection Control and Hospital Epidemiology 22, 35-40.
11. Go, E. S., Urban, C., Burns, J. et al. (1994). Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344, 1329-32.
12. Jones, M. E., Thornsberry, C., Livermore, D. M. et al. (1999). Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. Journal of Antimicrobial Chemotherapy 43 429-31.
13. Lyytikäinen, O., Köljalg, S., Härmä, M. et al. (1995). Outbreak caused by two multiresistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem. Journal of Hospital Infection 31, 41-54.
14. Rahal, J. J., Urban, C. & Segal-Maurer, S. (2002). Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clinical Infectious Diseases 34, 499-503.
15. Ruiz, J., Núñez, M. L., Pérez, J. et al. (1999). Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. European Journal of Clinical Microbiology and Infectious Diseases 18, 292-5.
16. Seifert, H., Baginski, R., Schulze, A. et al. (1993). Antimicrobial susceptibility of Acinetobacter species. Antimicrobial Agents and Chemotherapy 37, 750-3.
17. Takahashi, A., Yomoda, S., Kobayashi, I. et al. (2000). Detection of carbapenemase-producing Acinetobacter baumannii in a hospital. Journal of Clinical Microbiology 38, 526-9.
18. Tankovic, J., Legrand, P., de Gatines, G. et al. (1994). Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. Journal of Clinical Microbiology 32, 2677-81.
19. Towner, K. J. (1997). Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel. Journal of Medical Microbiology 46, 721-46.
20. Wisplinghoff, H., Edmond, M. B., Pfaller, M. A. et al. (2000). Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology and antimicrobial susceptibility. Clinical Infectious Diseases 31, 690-7.
21. Wood, G. C., Hanes, S. D., Croce, M. A. et al. (2002). Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator associated pneumonia. Clinical Infectious Diseases 34, 1425-30.
22. Corbella, X., Montero, A., Pujol, M. et al. (2000). Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. Journal of Clinical Microbiology 38, 4086-95.
23. Catchpole, C. R., Andrews, J. M., Brenwald, N. et al. (1997). A reassessment of the in-vitro activity of colistin sulphomethate sodium. Journal of Antimicrobial Chemotherapy 39 255-60.
24. Evans, M. E., Feola, D. J. & Rapp, R. P. (1999). Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Annals of Pharmacotherapy 33, 960-7.
25. Kucers, A., Crowe, S., Grayson, M. L., et al. (11997). Polymyxins. In The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn (Kucers, A., Crowe, S., Grayson, M. L. et al., Eds), pp. 667-75. Butterworth-Heinemann, Oxford, UK.
26. Garnacho-Montero, J., Ortiz-Leyva, C., Jiménez-Jiménez, F. J. et al. (2003). Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical Infectious Diseases 36, 1111-8.
27. Wolff, M., Joly-Guillou, M. L., Farinotti, R. et al. (1999). In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrobial Agents and Chemotherapy 43, 1406-11.
28. Rodríguez-Hernández, M. J., Pachón, J., Pichardo, C. et al. (2000). Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. Journal of Antimicrobial Chemotherapy 45, 493-501.
29. Montero, A., Ariza, J., Corbella, X. et al. (2002). Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 46 1946-52.
30. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing. Eleventh Informational Supplement, M100-S12. NCCLS, Villanova, PA, USA.
31. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - 5th Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA.
32. National Committee for Clinical Laboratory Standards. (1992). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Tentative Guideline, M26-T. NCCLS, Villanova, PA, USA.
33. Dalla-Costa, L. M., Coelho, J. M., Souza, H. et al. (2003). Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. Journal of Clinical Microbiology 41, 3403-6.
34. Lorian, V. (1996). Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 4th edn (Lorian, V., Ed.), pp. 339-41. Williams and Wilkins, MD, USA.
35. Esposito, A. L. & Pennington, J. E. (1983). Effects of aging on antibacterial mechanisms in experimental pneumonia. American Review of Respiratory Disease 128, 662-7.
36. Chastre, J. & Fagon, J. Y. (2002). Ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 165, 867-903.
37. Kaul, R., Burt, J. A., Cork, L. et al. (1996). Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality. Journal of Infectious Diseases 174, 1279-87.
38. Vila, J. A., Marcos, A., Marco, F. et al. (1993). In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 37, 138-41.
39. Lopez-Otsoa, F., Gallego, L., Towner, K. J. et al. (2002). Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. Journal of Clinical Microbiology 40 4741-3.
40. Fernández-Cuenca, F., Martínez-Martínez, L., Conejo, M. C. et al. (2003). Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 51, 565-74.
41. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-12.
42. Kucers, A., Crowe, S., Grayson, M. L., et al. (1997). Rifampicin (Rifampin). In The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn. (Kucers, A., Crowe, S., Grayson, M. L. et al., Eds), pp. 676-708. Butterworth-Heinemann, Oxford, UK.
43. Giamarellos-Bourboulis, E. J., Xirouchaki, E. & Giamarellou, H. (2001). Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease 40, 117-20.
44. Hogg, G. M., Barr, J. G. & Webb, C. H. (1998). In vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 41, 494-5.
45. Yoon, J., Urban, C., Terzian, C. et al. (2004). In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 48, 753-7.
46. Zhao, X. & Drlica, K. (2002). Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. Journal of Infectious Diseases 185 561-5.